Pharmanutra

Regulatory Filings • Feb 21, 2023

Informazione Regolamentata n. 20106-11-2023		Data/Ora Ricezione 21 Febbraio 2023 17:49:10	Euronext Star Milan
Societa'	:	PHARMANUTRA
Identificativo Informazione Regolamentata	:	172672
Nome utilizzatore	:	PHARMANUTRAN02 - Sarti Francesco
Tipologia	:	REGEM
Data/Ora Ricezione	:	21 Febbraio 2023 17:49:10
Data/Ora Inizio Diffusione presunta	:	21 Febbraio 2023 17:49:11
Oggetto	:	PR PHARMANUTRA S.P.A. - PHN - THE STRATEGIC GUIDELINES FOR THE NEXT YEARS WERE PRESENTED AT THE INVESTOR'S DAY
Testo del comunicato

Vedi allegato.

PHARMANUTRA S.P.A.: THE STRATEGIC GUIDELINES FOR THE NEXT YEARS WERE PRESENTED AT THE INVESTOR'S DAY.

Great response and interest from the audience of investors who met the Group's management team today

Pisa, February 21st , 2023 – PharmaNutra S.p.A. (MTA; Ticker PHN), a company specialized in mineral-based nutritional supplements and medical devices for muscles and joints, organized today in Milan its own "Investor Day".

The front line of the management of the Group represented by Andrea and Roberto Lacorte, founders and respectively Chairman and Vice President/CEO of Pharmanutra, Carlo Volpi, Chief Operating Officer, and Francesco Sarti, Chief Financial Officer, met the financial community to share strategic horizons of the Company in the coming years, illustrating the main drivers on which the development of the Company listed on the Euronext STAR segment of Borsa Italiana will be based.

The focus of the Investor Day of PharmaNutra S.p.A., leader in the production of iron-based nutritional supplements with the SiderAL® brand, where it boasts important patents related to Sucrosomial® Technology, were the excellent medium and long-term prospects of the Group companies, which in addition to the leading company PharmaNutra also includes Alesco S.r.l., Junia Pharma S.r.l. and Akern S.r.l. In particular, PharmaNutra's management showed the main growth boosters for the next 5-10 years, which will represent the strategic and right momentum to invest and capitalize on PharmaNutra's new long-term business opportunities. Strengthened by very solid economic fundamentals, the Group from Pisa will be able to seize and exploit as best as it can the market potential to consolidate and support current and future investments in the name of financial sustainability.

Relying on a strong international presence, high scientific expertise and enhancing first-level partnerships in the sports field, PharmaNutra reiterates its considerable development potential, forecasting a 2022- 2030 Sales CAGR growing by +10.9%, which could further increase up to +18.5% considering the strategic business lines that will be implemented from now to the next few years.

"Today was one of the most productive meetings with the investors: I would like to underline the high professional quality of the participants, the great attention and appreciation from all investors: every question

has been focused and appropriate to the discussion topics" declares Andrea Lacorte. "From our side we surprised them, as per Pharmanutra habit, and we can certainly expect a confidence proof in short and long terms. I am really satisfied of this Investor Day which give us the possibility to open our minds towards new business potential, thanks to the quality of the speakers".

"I am really happy to have met our investors especially in this moment where there is a great deal of attention towards Pharmanutra: our business, as never before, is experiencing a period full of growth drivers and in this regard it was essential to share with the investor audience the long-term projects regarding research and development, the current market and the international expansion which is taking shape in new important direction" explains Roberto Lacorte " There was a great recognition from investors, confirming how useful this Investor Day initiative was to their commitment to PharmaNutra in their respective investment programs. A real success, with great mutual satisfaction, which we will certainly repeat in the future to better share the company's investment, growth and development".

A very challenging and positive vision, passionately shared with the investors and an important audience of analysts, based on the significant growth potential of the Group, sustained by a stable expansion on the international market – to date there are already 70 countries in which the Group is present, a number intended to grow throughout the year – and on an internationally recognized scientific research, which has allowed to place products of the highest nutraceutical value on the market. An R&D activity, which with the new headquarter of the Group under construction in Pisa, will go through a further speed up, thanks to the internalization of some production processes.

The presentation showed today to investors is available on the Investor section on the website of the company www.pharmanutra.it

PharmaNutra S.p.A.

Founded and led by Chairman Andrea Lacorte and Deputy Chairman Roberto Lacorte, PharmaNutra is a company established in 2003 that develops unique food supplements and innovative nutrition devices by carrying out the entire production process, from the proprietary starting materials through to the finished product. The effectiveness of its products is demonstrated by a wealth of scientific evidence, including 135 publications involving more than 7000 subjects. The Group distributes and places its products on the market in Italy and abroad. Within Italy, sales activities are carried out through a network of over 160 medical science liaisons serving the medical profession, as well as focusing on the exclusive marketing of PharmaNutra products to pharmacies throughout the country. Sales activities are guaranteed abroad in 70 different countries through 47 partners chosen amongst the best pharmaceutical companies. PharmaNutra is a market leader in the manufacture of dietary supplements containing iron with its SiderAL® brand, where it boasts important patents covering its Sucrosomial® Technology. Over the years, the Group has developed a precise strategy regarding the management and production of intellectual property, based on integrated management of all the various components: proprietary starting materials, patents, brands and clinical evidence. PharmaNutra.it

For further information::

Via Delle Lenze, 216/b - 56122 Pisa Tel. +39 050 7846500 investorrelation@PharmaNutra.it

Internal Press Office press@calabughi.com

PharmaNutra S.p.A. Press Office - Spriano Communication & Partners

Via Santa Radegonda, 16 - 20121 Milan Tel. +39 02 83635708

Matteo Russo mrusso@sprianocommunication.com Cristina Tronconi ctronconi@sprianocommunication.com